{"id":"rlp2086-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by stimulating the body's immune system to produce a protective response against the virus, potentially preventing severe illness and death. The exact mechanism of action is not fully understood, but it is thought to involve the activation of immune cells and the production of antibodies that can recognize and neutralize the virus.","oneSentence":"rLP2086 vaccine is a vaccine that targets the SARS-CoV-2 virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:32.245Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19"}]},"trialDetails":[{"nctId":"NCT04645966","phase":"PHASE2","title":"A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-11-26","conditions":"Meningococcal Vaccine","enrollment":326},{"nctId":"NCT03135834","phase":"PHASE3","title":"A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-04-24","conditions":"Meningococcal Vaccine","enrollment":1610},{"nctId":"NCT01299480","phase":"PHASE2","title":"A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-03-03","conditions":"Meningococcal Vaccine","enrollment":1714},{"nctId":"NCT01323270","phase":"PHASE2","title":"A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-03-18","conditions":"Meningococcal Vaccine, rLP2086, Repevax","enrollment":753},{"nctId":"NCT02534935","phase":"PHASE2","title":"Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-08-31","conditions":"Meningococcal B Disease","enrollment":396},{"nctId":"NCT02531698","phase":"PHASE2","title":"A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-08","conditions":"MENINGOCOCCAL INFECTION","enrollment":400},{"nctId":"NCT01461980","phase":"PHASE2","title":"A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-09-28","conditions":"Vaccines, Meningococcal Vaccines","enrollment":2648},{"nctId":"NCT01768117","phase":"PHASE2","title":"Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-02","conditions":"Meningitis, Meningococcal, Serogroup B","enrollment":13},{"nctId":"NCT01461993","phase":"PHASE2","title":"A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-09-28","conditions":"Vaccines, Meningococcal Vaccines","enrollment":2499},{"nctId":"NCT01830855","phase":"PHASE3","title":"A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-04","conditions":"Meningococcal Vaccine","enrollment":3596},{"nctId":"NCT01352845","phase":"PHASE3","title":"A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-05","conditions":"Healthy","enrollment":3301},{"nctId":"NCT00879814","phase":"PHASE1","title":"Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-04","conditions":"Meningitis, Meningococcal","enrollment":48},{"nctId":"NCT00808028","phase":"PHASE2","title":"A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-02","conditions":"Meningitis, Meningococcal","enrollment":538},{"nctId":"NCT01352793","phase":"PHASE3","title":"A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-11","conditions":"Meningitis, Meningococcal","enrollment":5715},{"nctId":"NCT00798304","phase":"PHASE2","title":"Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants","status":"TERMINATED","sponsor":"Pfizer","startDate":"2009-01","conditions":"Meningitis, Meningococcal","enrollment":46},{"nctId":"NCT00387725","phase":"PHASE2","title":"Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Adolescents","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-11","conditions":"Healthy","enrollment":127},{"nctId":"NCT00780806","phase":"PHASE1, PHASE2","title":"Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-10","conditions":"Meningitis, Meningococcal","enrollment":60},{"nctId":"NCT00387569","phase":"PHASE1","title":"Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-10","conditions":"Healthy","enrollment":99},{"nctId":"NCT00297687","phase":"PHASE1","title":"Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-03","conditions":"Meningitis, Meningococcal","enrollment":108}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ACUTE KIDNEY INJURY"},{"count":1,"reaction":"BRAIN INJURY"},{"count":1,"reaction":"CARDIAC ARREST"},{"count":1,"reaction":"OVERDOSE"},{"count":1,"reaction":"SUICIDE ATTEMPT"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"rLP2086 vaccine","genericName":"rLP2086 vaccine","companyName":"Pfizer","companyId":"pfizer","modality":"Biologic","firstApprovalDate":"","aiSummary":"rLP2086 vaccine is a vaccine that targets the SARS-CoV-2 virus. Used for Prevention of COVID-19.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}